bioMérieux Lowers Annual Targets After a 3.9% Decline in First Quarter
The in vitro diagnostics group bioMérieux has revised its annual targets downward following a first quarter impacted by weak respiratory epidemiology and an uncertain macroeconomic context. The group's revenue amounted to 984 million euros, marking an organic decline of 3.9% for the period.
bioMérieux's consolidated revenue reached 984 million euros in the first quarter of 2026, down 10.4% in reported figures compared to 1,098 million euros in the first quarter of 2025. On a like-for-like basis, organic growth was minus 3.9%. This performance primarily reflects a collapse in sales of BIOFIRE® respiratory panels, which fell by 23% organically. Instrument sales also declined by 18% in a market unfavorable to new installations. Conversely, reagents from the GO-28 growth engines grew by 6.5% organically, driven notably by a 31% increase in SPOTFIRE® reagent sales and an 8% growth in industrial application reagents.
Revised Outlook for 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In light of these performances and the current market dynamics, bioMérieux has revised its outlook for 2026 downward. Annual sales are now expected to grow organically between 3% and 5%, compared to a previous range of 5% to 7%. The organic growth of the annual contributory operating profit is lowered to between 0% and 10%, whereas the group previously aimed for at least 10%, excluding a prolonged impact of events in the Middle East. The group confirms a negative foreign exchange impact of between 50 and 60 million euros on the 2026 contributory operating profit. The impact of the US dollar weighed 73 million euros on sales for the past quarter.
Sales by Application
By application, sales in clinical applications, which represent 84% of total revenue, declined by 5% organically to reach 825 million euros. Non-respiratory BIOFIRE® panels recorded a growth of 4%, driven by the Blood Culture Identification and Joint Infection ranges. SPOTFIRE® advanced by 15%, with a 31% increase in reagent sales and an installed base exceeding 6,800 units. Microbiology progressed by 2%, while industrial applications grew by 5%. Geographically, North America experienced a decline of 7%, Latin America progressed by 16%, Europe-Middle East-Africa retracted by 1%, and Asia-Pacific decreased by 8%.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
